Telix Pharmaceuticals Ltd. (TLX)
9.85
+0.07
(+0.72%)
USD |
NASDAQ |
Dec 05, 16:00
9.60
-0.25
(-2.54%)
After-Hours: 06:51
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.297B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -38.44% |
| Valuation | |
| PE Ratio | 317.74 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.105 |
| Price to Book Value | 27.90 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. |
| URL | http://www.telixpharma.com |
| Investor Relations URL | https://ir.telixpharma.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 19, 2026 (est.) |
| Last Earnings Release | Aug. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. |
| URL | http://www.telixpharma.com |
| Investor Relations URL | https://ir.telixpharma.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 19, 2026 (est.) |
| Last Earnings Release | Aug. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |